Loss of TDAG51 Results in Mature-Onset Obesity, Hepatic Steatosis, and Insulin Resistance by Regulating Lipogenesis

  1. Richard C. Austin1,2
  1. 1Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  2. 2Hamilton Centre for Kidney Research, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada
  3. 3Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  4. 4Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
  1. Corresponding author: Richard C. Austin, austinr{at}taari.ca.

Abstract

Regulation of energy metabolism is critical for the prevention of obesity, diabetes, and hepatic steatosis. Here, we report an important role for the pleckstrin homology–related domain family member, T-cell death–associated gene 51 (TDAG51), in the regulation of energy metabolism. TDAG51 expression was examined during adipocyte differentiation. Adipogenic potential of preadipocytes with knockdown or absence of TDAG51 was assessed. Weight gain, insulin sensitivity, metabolic rate, and liver lipid content were also compared between TDAG51-deficient (TDAG51−/−) and wild-type mice. In addition to its relatively high expression in liver, TDAG51 was also present in white adipose tissue (WAT). TDAG51 was downregulated during adipogenesis, and TDAG51−/− preadipocytes exhibited greater lipogenic potential. TDAG51−/− mice fed a chow diet exhibited greater body and WAT mass, had reduced energy expenditure, displayed mature-onset insulin resistance (IR), and were predisposed to hepatic steatosis. TDAG51−/− mice had increased hepatic triglycerides and SREBP-1 target gene expression. Furthermore, TDAG51 expression was inversely correlated with fatty liver in multiple mouse models of hepatic steatosis. Taken together, our findings suggest that TDAG51 is involved in energy homeostasis at least in part by regulating lipogenesis in liver and WAT, and hence, may constitute a novel therapeutic target for the treatment of obesity and IR.

Footnotes

  • Received February 29, 2012.
  • Accepted July 17, 2012.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

| Table of Contents

This Article

  1. Diabetes vol. 62 no. 1 158-169
  1. Supplementary Data
  2. All Versions of this Article:
    1. db12-0256v1
    2. 62/1/158 most recent